Inventor · disambiguated record
Finn Myhren
Also filed as: MYHREN FINN
23 granted patents·15 pending applications·157 citations·filing 1992–2024
94Inventor score
Files withAKER BIOMARINE ANTARCTIC AS15NORSK HYDRO AS7CLAVIS PHARMA AS4AKER BIOMARINE HUMAN INGREDIENTS AS3AHRABI SAYEH2
Top patents by PatentIndex Score
38 records- 0187US10864223B2Lipid compositionsAKER BIOMARINE ANTARCTIC AS·Filed 2016·Granted Dec 15, 2020·2 cites·14 claims
- 0280US11065267B2Lysophosphatidylcholine compositionsAKER BIOMARINE ANTARCTIC AS·Filed 2018·Granted Jul 20, 2021·0 cites·17 claims
- 0379US6384019B1Gemcitabine derivativesNORSK HYDRO AS·Filed 1998·Granted May 7, 2002·50 cites·32 claims
- 0479US2025090561A1Lysophosphatidylcholine compositionsAKER BIOMARINE ANTARCTIC AS·Filed 2024·Application pending·0 cites
- 0578US2024082276A1Lipid compositionsAKER BIOMARINE ANTARCTIC AS·Filed 2023·Application pending·0 cites
- 0677US6762175B2Fatty acid derivativesNORSK HYDRO AS·Filed 2002·Granted Jul 13, 2004·9 cites·6 claims
- 0777US6153594A5'-O-acylated antiviral nucleosidesNORSK HYDRO AS·Filed 1994·Granted Nov 28, 2000·46 cites·9 claims
- 0876US2024382453A1Protein hydrolysatesAKER BIOMARINE UNDERSTORY AS·Filed 2024·Application pending·0 cites
- 0973US8399420B2Azacytidine analogues and uses thereofSILVERMAN LEWIS·Filed 2008·Granted Mar 19, 2013·3 cites·21 claims
- 1072US12076333B2Lysophosphatidylcholine compositionsAKER BIOMARINE HUMAN INGREDIENTS AS·Filed 2021·Granted Sep 3, 2024·0 cites·17 claims
- 1172US11819509B2Lipid compositionsAKER BIOMARINE ANTARCTIC AS·Filed 2020·Granted Nov 21, 2023·0 cites·16 claims
- 1271US8722041B2Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereofSANDVOLD MARIT L·Filed 2011·Granted May 13, 2014·2 cites·9 claims
- 1369US12023359B2Phospholipid compositions for delivery of therapeutic compoundsAKER BIOMARINE HUMAN INGREDIENTS AS·Filed 2023·Granted Jul 2, 2024·0 cites·18 claims
- 1469US11020438B2Phospholipid compositions and their preparationAKER BIOMARINE ANTARCTIC AS·Filed 2019·Granted Jun 1, 2021·0 cites·8 claims
- 1569US2022273618A1Protein hydrolysatesAKER BIOMARINE ANTARCTIC AS·Filed 2022·Application pending·0 cites
- 1667US12427171B2Krill oil composition enriched in LPC-DHA and LPC-EPAAKER BIOMARINE HUMAN INGREDIENTS AS·Filed 2023·Granted Sep 30, 2025·0 cites·17 claims
- 1765US9428540B2Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agentsMYHREN FINN·Filed 2008·Granted Aug 30, 2016·2 cites·2 claims
- 1864US2019231744A1Protein hydrolysatesAKER BIOMARINE ANTARCTIC AS·Filed 2019·Application pending·0 cites
- 1963US6316425B1Therapeutic agentsNORSK HYDRO AS·Filed 1996·Granted Nov 13, 2001·18 cites·13 claims
- 2061US6548486B1Fatty acid esters of nucleoside analogsNORSK HYDRO AS·Filed 1992·Granted Apr 15, 2003·17 cites·43 claims
- 2160US2018133263A1Phospholipid compositions and their preparationAKER BIOMARINE ANTARCTIC AS·Filed 2018·Application pending·0 cites
- 2257US11744864B2Method of treating eye diseases with krill oilAKER BIOMARINE ANTARCTIC AS·Filed 2021·Granted Sep 5, 2023·0 cites·19 claims
- 2357US9867856B2Phospholipid compositions and their preparationAKER BIOMARINE ANTARCTIC AS·Filed 2015·Granted Jan 16, 2018·0 cites·7 claims
- 2455US2014249298A1ANTI-HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (hENT1) ANTIBODIES ADN METHODS OF USE THEREOFUNIV ALBERTA·Filed 2014·Application pending·0 cites
- 2552US10456412B2Lipid extraction processesAKER BIOMARINE ANTARCTIC AS·Filed 2016·Granted Oct 29, 2019·0 cites·11 claims
- 2652US2004063677A1Methods of treating disorders using lipophilic derivativesNORSK HYDRO AS·Filed 2003·Application pending·0 cites
- 2751US10960016B2Capsules containing high doses of krill phospholipidsAKER BIOMARINE ANTARCTIC AS·Filed 2015·Granted Mar 30, 2021·0 cites·7 claims
- 2851US6335322B1Therapeutic agentsNORSK HYDRO AS·Filed 1999·Granted Jan 1, 2002·8 cites·10 claims
- 2946US2023038627A1Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapyAKER BIOMARINE ANTARCTIC AS·Filed 2020·Application pending·0 cites
- 3045US8349834B2Dioxolane derivates for the treatment of cancerCLAVIS PHARMA AS·Filed 2006·Granted Jan 8, 2013·0 cites·7 claims
- 3145US2008280851A1Oral Dosage Forms of Gemcitabine DerivativesCLAVIS PHARMA AS·Filed 2006·Application pending·0 cites
- 3244US2007225248A1Oral dosage forms of gemcitabine derivativesCLAVIS PHARMA AS·Filed 2006·Application pending·0 cites
- 3343US2013005678A1Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-ElaidateCLAVIS PHARMA ASA·Filed 2011·Application pending·0 cites
- 3439US2007135436A1Chemical compoundsCLAVIS PHARMA AS·Filed 2005·Application pending·0 cites
- 3535US10806742B2Liquid phospholipid-containing compositions for the preparation of pharmaceuticalsAKER BIOMARINE ANTARCTIC AS·Filed 2015·Granted Oct 20, 2020·0 cites·3 claims
- 3629US2001006962A1Fatty acid derivativesFiled 1998·Application pending·0 cites
- 3725US8912162B2Parenteral formulations of elacytarabine derivativesAHRABI SAYEH·Filed 2011·Granted Dec 16, 2014·0 cites·18 claims
- 3821US2011281815A1Parental formulations of gemcitabine derivativesAHRABI SAYEH·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →